A European partner in Life Science
Our vision is to improve people's lives by being a leading, value-adding partner in Life Science
Interim Report Q3 2025
Share price
Press Releases
Report
Calendar
-
Good organic growth and strong earnings performance
comments by the ceoMargin improvements remain the highest priority, and during the quarter, profitability was clearly strengthened in both business areas. The margin improvements are mainly driven by ongoing efficiency initiatives, a continuous shift in the product portfolio towards more advanced, as well as active pricing efforts. Organic growth in the quarter was driven by positive developments in both business areas. Our acquisitions have developed well, with strong growth, improved margins, and significantly improved cash flows. Profit for the period improved by 228 percent in the quarter.
![Fredrik Dalborg Addlife Q3 2025 Sq]()
-
Stories from our subsidiaries
From the very beginning, I was struck by AddLife’s personal approach and authentic company culture. They didn’t just see a business, they saw people, potential, and purpose.
![Anand En Groep500]()
-
![Quote]()
Right chemistry from the start
- Michael Hartman, entrepreneur and former co-owner of BioCat
Stories from our subsidiariesEvery step of the process, from initial talks to signing the contract, was pragmatic, straightforward, and quick.
![Biocat 2022]()
Our business areas
MEDTECH
In the Medtech business area, the subsidiaries offer products and services in medical technology, as well as assistive equipment and digital solutions for use in home care. Medtech has two business units - Hospital and Homecare. The Medtech offering mainly focuses on publicly funded healthcare, home care and social care in Europe.
Read more
LABTECH
The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.
Read moreJoin the AddLife group
Do you have a Life Science company with opportunities to grow? We offer an attractive option with a decentralized business model where we combine the strength of a large enterprise with the dedication and business skills of an entrepreneur. As an AddLife subsidiary, you are responsible for your business activities within the AddLife requirements for growth, profitability and sustainable development.
News from our subsidiaries
From the very beginning, I was struck by AddLife’s personal approach and authentic company culture. They didn’t just see a business, they saw people, potential, and purpose.
Every step of the process, from initial talks to signing the contract, was pragmatic, straightforward, and quick.
Like our colleagues in Sweden, last June we joined their traditional summer welcome celebration with our very own MBA Midsommar.
The significant technological advancements in Robotics will help us to drive growth and future proof our businesses to the evolving needs of their customers to help improve lives in the most efficient way possible.
Sustainability for AddLife
Sustainability is a central part of AddLife's vision to improve people's life by being a leading, value adding provider in Life Science. AddLife´s approach to sustainability is identified through three impact areas where we can have the greatest contribution to a long-term lasting business and society.
